Loviride

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Loviride
Loviride.png
Systematic (IUPAC) name
2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
Identifiers
ATC code none
PubChem CID 3963
ChemSpider 3826 YesY
UNII 3S1R1LZ09H N
KEGG D04786 YesY
ChEMBL CHEMBL37624 YesY
Synonyms R089439
Chemical data
Formula C17H16Cl2N2O2
Molar mass 351.227 g/mol
 NYesY (what is this?)  (verify)

Loviride (also called loveride[citation needed]) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an Non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance the NNRTIs efavirenz and nevirapine.

Synthesis[edit]

Loviride synthesis: Janssen Pharmaceutica U.S. Patent 5,407,961 (1995).

External links[edit]